Cedric Francois is CEO at Apellis Pharmaceuticals, Inc. (APLS). They have made 34 open-market trades across 1 company since 2019, most recently 2026-05-14.
CIK 0001658080
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 34 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| APLS | 143,750 | $5.9M |
Shares reported on the most recent Form 4, priced at the 2026-05-14 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| APLS | SELL | 2026-01-22 | 2026-01-23 | $21.77 | $592K | +7.2% | +4.1% | +89.6% |
| APLS | SELL | 2026-01-20 | 2026-01-21 | $19.79 | $162K | +9.0% | +6.3% | +95.4% |
| APLS | SELL | 2026-01-13 | 2026-01-15 | $22.19 | $226K | +12.4% | +5.1% | +99.0% |
| APLS | SELL | 2025-08-27 | 2025-08-29 | $28.23 | $12.7M | -7.7% | -17.8% | -22.7% |
| APLS | SELL · 10b5-1 | 2025-07-17 | 2025-07-18 | $20.21 | $797K | -3.8% | +38.4% | +22.2% |
| APLS | SELL · 10b5-1 | 2025-07-14 | 2025-07-16 | $20.19 | $5.6M | -5.2% | +40.4% | +17.1% |
| APLS | SELL | 2025-01-29 | 2025-01-30 | $29.52 | $167K | -5.8% | -20.6% | -36.6% |
| APLS | SELL | 2025-01-22 | 2025-01-23 | $30.43 | $825K | -6.4% | -10.8% | -43.1% |
| APLS | SELL | 2025-01-17 | 2025-01-21 | $29.96 | $360K | -3.4% | -5.6% | -39.9% |
| APLS | SELL | 2025-01-13 | 2025-01-14 | $28.70 | $359K | +5.2% | -3.1% | -31.8% |
| APLS | SELL · 10b5-1 | 2024-03-01 | 2024-03-05 | $64.12 | $32.0M | -8.5% | -9.6% | -35.3% |
| APLS | SELL | 2024-02-12 | 2024-02-13 | $67.77 | $537K | +7.0% | -15.8% | -35.8% |
| APLS | SELL | 2024-01-29 | 2024-01-31 | $64.14 | $365K | +6.8% | +0.7% | -30.4% |
| APLS | SELL | 2024-01-22 | 2024-01-23 | $65.00 | $873K | -6.3% | +1.3% | -28.6% |
| APLS | SELL | 2024-01-16 | 2024-01-17 | $66.81 | $1.0M | -1.8% | +3.3% | -22.2% |
| APLS | SELL | 2023-11-21 | 2023-11-21 | $48.80 | $244K | +29.0% | +10.0% | +37.1% |
| APLS | SELL | 2023-09-01 | 2023-09-01 | $41.75 | $12.5M | +1.3% | -13.2% | +26.0% |
| APLS | SELL | 2023-05-16 | 2023-05-18 | $85.72 | $5.0M | -2.9% | -0.3% | -64.7% |
| APLS | SELL · 10b5-1 | 2023-04-18 | 2023-04-20 | $82.02 | $2.5M | +1.1% | +6.3% | -50.8% |
| APLS | SELL | 2023-03-21 | 2023-03-23 | $62.74 | $1.9M | +24.0% | +41.0% | +38.9% |
| APLS | SELL | 2022-12-19 | 2022-12-21 | $52.06 | $2.9M | -3.2% | +0.6% | +20.0% |
| APLS | SELL | 2020-12-15 | 2020-12-16 | $52.16 | $522K | +4.3% | -0.5% | -13.5% |
| APLS | SELL | 2020-11-16 | 2020-11-17 | $39.38 | $197K | +13.5% | +28.2% | +7.7% |
| APLS | SELL | 2020-10-15 | 2020-10-16 | $34.46 | $172K | -7.5% | +9.9% | +53.3% |
| APLS | SELL | 2020-09-15 | 2020-09-16 | $30.96 | $155K | -4.0% | +12.0% | +69.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.